Eftychia Chatziioannou

6PUBLICATIONS
14CO-AUTHORS
Predictive and prognostic markersMolecular targetsGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 09, 2024
Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic Target.

Matti Böcker, Eftychia Chatziioannou, Heike Niessner

|Oct 22, 2024
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.

Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou

|Sep 07, 2023
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo.

Lisa Marie Fröhlich, Heike Niessner, Birgit Sauer

|May 04, 2023
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.

Eftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas

Pageof 1

Frequent Collaborators

2 joint publications

Teresa Amaral

2 joint publications

Heike Niessner

2 joint publications

Tobias Sinnberg

1 joint publications

Lisa Marie Fröhlich